Paid Clinical Trials Manchester

Discover 232 paid clinical trials in Manchester, New Hampshire. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 232

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Recruiting

PHASE2

Sponsor:

SWOG Cancer Research Network

Location:

Concord, Brewer, Ephrata, Lebanonshow 69 more

Code:

NCT06116682

Conditions

Lung Non-Small Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Amivantamab

Biospecimen Collection

Computed Tomography

Magnetic Resonance Imaging

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Recruiting

PHASE3

Sponsor:

AbbVie

Location:

Boston, Worcester, Quincy, Farmingtonshow 71 more

Code:

NCT05889182

Conditions

Hidradenitis Suppurativa

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Upadacitinib

Placebo

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Recruiting

PHASE2

Sponsor:

Nektar Therapeutics

Location:

Portsmouth, Sherbrooke, New York, Camp Hillshow 11 more

Code:

NCT06340360

Conditions

Alopecia Areata

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Rezpegaldesleukin

Placebo

A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis

Recruiting

PHASE2

PHASE3

Sponsor:

Regeneron Pharmaceuticals

Location:

Boston, Lebanon, Farmington, Bristolshow 42 more

Code:

NCT05831176

Conditions

Eosinophilic Gastritis

Eosinophilic Duodenitis

Eosinophilic Gastrointestinal Disease

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Dupilumab Dose 1

Dupilumab Dose 2

Matching Placebo

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting

PHASE3

Sponsor:

Takeda

Location:

Portsmouth, Lebanon, Stony Brook, Bronxshow 86 more

Code:

NCT06550076

Conditions

Plaque Psoriasis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TAK-279

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting

PHASE2

Sponsor:

NYU Langone Health

Location:

Belmont, Newton, Lebanon, Fall Rivershow 16 more

Code:

NCT04464980

Conditions

Opioid Use Disorder (OUD)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SL-BUP

XR-BUP

XR-NTX

MMR

MILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims Study

Recruiting

Sponsor:

Vertos Medical, Inc.

Location:

Manchester, Bedford, Nashua, Strathamshow 944 more

Code:

NCT03072927

Conditions

Lumbar Spinal Stenosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MILD

Interspinous Process Decompression

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Recruiting

PHASE3

Sponsor:

AbbVie

Location:

Boston, Lebanon, Portland, Brooklynshow 74 more

Code:

NCT05814627

Conditions

Rheumatoid Arthritis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Upadacitinib

Adalimumab

Upadacitinib Matching Placebo

Adalimumab Matching Placebo

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

Recruiting

PHASE3

Sponsor:

Intec Pharma Ltd.

Location:

Boston, Lebanon, Vernon, Commackshow 32 more

Code:

NCT02615873

Conditions

Parkinson's Disease

Eligibility Criteria

Sex: All

Age: 30 - 70+

Healthy Volunteers: Not accepted

Interventions

Accordion Pill™ Carbidopa/Levodopa

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

Recruiting

PHASE1

Sponsor:

Regeneron Pharmaceuticals

Location:

Boston, New York, New Brunswick, Louisvilleshow 2 more

Code:

NCT05685173

Conditions

B-cell Non-Hodgkins Lymphoma (B-NHL)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Odronextamab

REGN5837